Dicerna Pharmaceuticals, Inc. (DRNA) Reaches $11.38 After 4.00% Down Move; Allianzgi Convertible & Income Fund (NCV)’s Sentiment Is 2

April 23, 2018 - By Marie Mckinney

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Logo

Allianzgi Convertible & Income Fund (NCV) investors sentiment increased to 2 in 2017 Q4. It’s up 1.35, from 0.65 in 2017Q3. The ratio increased, as 26 investment professionals started new or increased positions, while 13 cut down and sold stock positions in Allianzgi Convertible & Income Fund. The investment professionals in our database reported: 9.79 million shares, up from 9.25 million shares in 2017Q3. Also, the number of investment professionals holding Allianzgi Convertible & Income Fund in top ten positions was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 9 Increased: 16 New Position: 10.

The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) is a huge mover today! The stock decreased 5.25% or $0.63 during the last trading session, reaching $11.38. About 1.03 million shares traded or 87.73% up from the average. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has risen 274.53% since April 23, 2017 and is uptrending. It has outperformed by 262.98% the S&P500.The move comes after 7 months negative chart setup for the $589.11 million company. It was reported on Apr, 23 by Barchart.com. We have $10.92 PT which if reached, will make NASDAQ:DRNA worth $23.56M less.

E&G Advisors Lp holds 0.43% of its portfolio in AllianzGI Convertible & Income Fund for 145,621 shares. Vident Investment Advisory Llc owns 357,453 shares or 0.11% of their US portfolio. Moreover, Next Financial Group Inc has 0.08% invested in the company for 26,190 shares. The Georgia-based Capital Investment Advisors Llc has invested 0.06% in the stock. Nine Masts Capital Ltd, a Hong Kong-based fund reported 55,500 shares.

The stock increased 0.19% or $0.0127 during the last trading session, reaching $6.7927. About 154,575 shares traded. AllianzGI Convertible & Income Fund (NCV) has risen 1.69% since April 23, 2017 and is uptrending. It has underperformed by 9.86% the S&P500.

Analysts await Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) to report earnings on May, 14. They expect $-0.30 earnings per share, up 55.88% or $0.38 from last year’s $-0.68 per share. After $-0.90 actual earnings per share reported by Dicerna Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -66.67% EPS growth.

Investors sentiment increased to 3 in 2017 Q4. Its up 2.21, from 0.79 in 2017Q3. It is positive, as 6 investors sold Dicerna Pharmaceuticals, Inc. shares while 5 reduced holdings. 18 funds opened positions while 15 raised stakes. 29.10 million shares or 180.62% more from 10.37 million shares in 2017Q3 were reported. California Pub Employees Retirement Sys has 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Cormorant Asset Mgmt Ltd Llc owns 3.46% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 3.66 million shares. Goldman Sachs Grp stated it has 0% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). 168,400 were accumulated by Deutsche Fincl Bank Ag. Renaissance Technology Limited Liability Co invested in 0.01% or 560,300 shares. Manufacturers Life The stated it has 806 shares. Morgan Stanley holds 1,874 shares or 0% of its portfolio. 683 Capital Management Limited reported 550,000 shares or 0.42% of all its holdings. 1.00M were reported by Camber Mngmt Limited Liability Company. Alpine Glob Lc reported 11,473 shares. Bank & Trust Of Mellon holds 19,579 shares or 0% of its portfolio. The North Carolina-based Bancorp Of America De has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Emerald Mutual Fund Advisers stated it has 0.2% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Adage Cap Prtn Group Ltd Liability Corp owns 1.98M shares or 0.04% of their US portfolio. Jpmorgan Chase & stated it has 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA).

Among 9 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 4 have Buy rating, 0 Sell and 5 Hold. Therefore 44% are positive. Dicerna Pharmaceuticals had 25 analyst reports since August 7, 2015 according to SRatingsIntel. The company was maintained on Wednesday, August 16 by Cowen & Co. The firm earned “Buy” rating on Monday, February 5 by SunTrust. The company was initiated on Friday, March 9 by Chardan Capital Markets. The rating was initiated by Cowen & Co on Tuesday, September 8 with “Outperform”. The company was maintained on Monday, August 15 by Chardan Capital Markets. As per Friday, March 9, the company rating was maintained by Stifel Nicolaus. H.C. Wainwright downgraded Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) on Friday, March 23 to “Neutral” rating. The firm has “Buy” rating given on Friday, August 11 by H.C. Wainwright. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Buy” rating by Cowen & Co on Tuesday, July 18. As per Thursday, June 30, the company rating was maintained by Stifel Nicolaus.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The company has market cap of $589.11 million. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It currently has negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Marie Mckinney

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: